Glioblastoma multiforme (GBM) is the most lethal brain malignancy which involves multi-gene abnormality. Unfortunately, effective therapy against GBM remains lacking. Previously, we found that NRP-1 and its downstream NRP-1/GIPC1 pathway played an important role in GBM. In our study, we further investigated the upstream signaling of NRP-1 to understand how it is regulated. First, we identified that hsa-miR-124-3p was miRNA differentially expressed in GBM and in normal brain tissues by high-throughput sequencing. Then, by dual luciferase reporter gene, we found miR-124-3p can specially bind to the 3 0 UTR region of the NRP-1 thus suppresses its expression. Moreover, miR-124-3p overexpression significantly inhibited GBM cell proliferation, migration and tumor angiogenesis which resulted in GBM apoptosis and cell cycle arrest, putatively via NRP-1 mediated PI3K/Akt/NFjB pathways activation in GBM cells. Meanwhile, miR-124-3p overexpression also suppressed tumor growth and reduced tumor angiogenesis when targeted by NRP-1 in a PDX model. Furthermore, NRP-1 mAb exerted synergistic inhibitory effects with miR-124-3p overexpression in GBM. Thus, we discovered that miR-124-3p acts as the upstream suppressor of NRP-1 which promotes GBM cell development and growth by PI3K/Akt/NFjB pathway. The miR-124-3p/NRP-1/ GIPC1 pathway as a new pathway has a vital role in GBM, and it could be considered as the potential target for malignant gliomas in future.
Introduction
Malignant gliomas, such as glioblastoma multiforme (GBM), are the most frequent primary malignant tumors (accounts for at least 70%) in the central nervous system. 1 Over decades, the efforts to optimize the standard treatments including combining multi-therapies (surgery, chemotherapy or radiotherapy) received no significant increase in improving the median survival of the GBM patients. 2, 3 GBM, the highest grade of gliomas, is characterized by high invasion, migration and proliferation abilities, with high malignancy rate and abundant blood supply and is well known as a refractory tumor to most of chemical therapeutics. With the advancement of molecular biology, molecular targeted therapeutic as a novel therapeutic strategy, has vastly been explored in many cancers, including gliomas. [4] [5] [6] MicroRNA is a small non-coding RNA with approximately 20-25 nucleotides in length, which regulates gene expression post-transcriptionally by antisense binding with complementary sequences of the specific 3 0 -UTR of target messenger RNA (mRNA). Then, miRNA either degrades target mRNA or inhibits its translation into protein. Therefore, miRNA is always considered as a more promising molecular drug for treating various diseases. Current evidence indicates that miRNA plays critical roles in cell development and biological processes, including regulation of tumor occurrence and development, and has positive or negative effects (as oncogenes or tumor suppressor gene) on tumor cell proliferation, apoptosis and invasion. 7, 8 Moreover, various miRNAs have been reported to be associated with gliomas, such as miR-21, miR-23a, miR-124, miR-128, miR-137, miR-145, miR-155, miR-218 and miR329. [9] [10] [11] In particular, miR-124 has been extensively examined in many studies, and it is obviously downregulated in various cancers including human glioma compared to normal tissues.
Neuropilin-1 (NRP-1) as a multi-functional receptor is expressed on various human neoplasms including gliomas, and the degree of expression is correlated with the clinicpathological features of host tumors. 15 Our previous studies [16] [17] [18] have verified that NRP-1 was overexpressed in both glioma cell lines and tissues, and played an important role in tumorgenesis, development, invasion and angiogenesis. Except binding to various extracellular receptors such as class 3 semaphorins (SEMA3), vascular endothelial growth factor (VEGF) or transforming growth factor b1 (TGF-b1) by its CUB (a1/a2) domains and/or b1/b2 domains, 19, 20 NRP-1 could also interact with intracellular protein GIPC1 via the cytoplasmic C-terminal SEA motif. Previously, we discovered that NRP-1/GIPC1-APPL1/p130Cas-KRAS/ERK pathway plays a crucial role in glioma progression. 18 However, the mechanism that how NRP-1 was regulated in gliomas still remains unclear.
In our study, we discovered the low expression of miR-124-3p in human gliomas which negatively regulates NRP-1 via binding to its 3 0 UTR region. Overexpression of miR-124-3p can reverse NRP-1 expression in both U87 and U251 glioma cells or in vivo PDX glioma model. As the consequence of its overexpression, it compromises proliferation, invasion and migration of glioma cells, confines tumor angiogenesis and increases cell apoptosis and cell cycle arrest. Furthermore, miR-124-3p also altered the signaling level of PI3K/ Akt/NFjB and ERK/c-Myc pathways in gliomas. Therefore, we revealed that miR-124-3p suppressed glioma cell development and growth by inhibiting its target NRP-1.
Materials and Methods

Human brain tissue samples and cell lines
According to the approved protocol of the institutional review board of Southeast University, all procedures were performed under the supervision of committee of Zhongda Hospital Southeast University. The informed consents were provided from patients who were diagnosed as grades III-IV gliomas by the criteria of World Health Organization (WHO). After collection, each glioma tissue was separated into 2 pieces -one was immediately frozen in liquid nitrogen and the other was embedded in paraffin. Normal brain tissues were obtained during surgeries of traumatic brain injury after informed consent was obtained. Human glioma cell lines U251 and U87 were obtained from the American Type Culture Collection (ATCC, VA, USA), and Glioblastoma SHG44 cell line was obtained from the China Center for Typical Culture Collection (CCTCC, Hubei, China). All cell lines were maintained at 378C in 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM, Gibco, MA, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone, MA, USA).
Quantitative RT-PCR
Total RNA from normal brain tissues, glioma tissues and cells was isolated using TRIzol reagent (Invitrogen, CA, USA). Synthesis of cDNA was done by using the Transcriptor First Strand cDNA Synthesis Kit (TIANGEN, BeiJing, China). Quantitative RT-PCR was carried out using Applied Biosystems StepOne 
High-throughput sequencing and bioinformatics analyses
After total RNA was isolated, small RNAs of 18-30 nt were obtained from 200 lg of total RNA by 15% denaturing polyacrylamide gel electrophoresis (PAGE). The size-selected small RNAs were subsequently ligated to 3 0 and 5 0 RNA adaptors with T4 RNA ligase and then used to synthesize the first-strand of cDNA. After amplification by RT-PCR with adaptor primers for 17 cycles, the PCR products were purified and submitted for sequencing via an Illumina Hi-Seq 2000 platform. Statistical analyses and data normalization were conducted using the Genespring GX software (Agilent Technologies, CA, USA). Differential miRNAs with twofold change in expression were considered to analyze. Predicted miRNA targets or predicted genes were detected using the miRWalk, TargetScan and miRanda databases.
Plasmids construction and stable cell lines transfection
Full-length splicing primers of NRP1 were designed by PCRbased accurate synthesis (PAS), the target sequence of the NRP-1 3 0 -UTR containing the predicted miR-124-3p binding sites
What's new? Glioblastoma multiforme (GBM) is associated with a number of different genetic alterations and with changes in the expression of microRNAs (miRNAs). In this study, the miRNA miR-124-3p was found to be differentially expressed in GBM vs. normal brain tissue. Molecular analyses further revealed that miR-124-3p specifically targets neuropilin-1 (NRP-1), binding to the NRP-1 3'UTR region, and that miR-124-3p upregulation is associated with inhibition of the PI3K/Akt/NKjB signaling pathway. In a patient-derived xenograft glioma model, overexpression of miR-124-3p was associated with suppressed GBM tumor growth and reduced angiogenesis. The findings suggest that miR-124-3p/NRP-1 signaling is a potential therapeutic target in GBM.
and its mutant of the miR-124-3p binding sites were synthesized by Nanjing Zoonbio Biotech Co., Ltd, Jiangsu, China (hsa-miR-124-3 P: 3 0 ccGUA-AGUGGCG-CACGGAAu 5 0 ; NRP-1: 5 0 ucUAUGUCCUCUCAAGUGCCUUu 3 0 ; NRP-1 mut: 5 0 ucUCGGUACUAUCAAGCGAACUu 3 0 NRP1). The resulting fragments were subcloned into the Nhe I and Asc I sites of the pmirGLO Dual-Luciferase miRNA Target Expression Vector or Mut-Vector (Promega, WI, USA). The cell transfections were carried out with FuGENE HD reagent (Roche, Basel, Switzerland). For selection of glioma stable cell lines, HEK293T was used to generate lentiviral particles. In brief, packaging mix were transfected into HEK293T cells with miR-124-3p overexpression plasmid, then lentiviral particles were harvested after 48 hr and filtered for subsequent usage. Stable cells with miR-124-3p overexpression were obtained in 400 mg/ mL neomycin (G418) for 14 days after transfection. The expression of miR-124-3p and NRP-1 was confirmed by qRT-PCR.
Dual-luciferase reporter assay
For the luciferase reporter assay, the 3 0 UTR of NRP-1, including the predicted binding sites for miR-124-3p, was cloned into the pGL3 luciferase reporter vector (Promega, WI, USA). The 3 0 UTR sequences were amplified from human cDNA by PCR, and a mutant NRP-1 3 0 UTR was constructed carrying a mutated sequence in the miR-124-3p binding region. Cells were cultured in 24-well plates and transfected with a complex of miR-124-3p and the luciferase reporter vectors; the pRLSV40 Renilla luciferase construct was used for normalization. After 48 hr incubation, luciferase activity was measured using a dual-luciferase reporter system according to the manufacturer's protocol (Promega, WI, USA).
MTT assay
Cells were seeded into 96-well plates at 3 3 10 4 cells per well in 100 lL of supplemented DMEM. After 48 hr, 10 lL of a dilution of MTT (5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, KeyGEN, Jiangsu, China) was added into each well and the cells were incubated at 378C for 4 hr. The optical density was measured at 490 nm wavelength, and the data were expressed as a percentage of control optical density.
In vitro transwell invasion assays
After 48 hr transfection, U87MG and U251MG cells to be assayed were added into 24-well plates with an 8-mm-pore polycarbonate membrane, which was coated with 20 mg of Matrigel (BD Biosciences, NJ, USA). Cells in the upper chamber were cultured in 200 lL of serum-free medium, and medium containing 20% FBS was added to the lower chamber to serve as a chemoattractant. After incubation for 24 hr, noninvasive cells were removed from the top well, and the invasive cells were then fixed with 4% paraformaldehyde for 10-30 min, stained with 0.1% crystal violet, and photographed (3100) in six independent fields for each well. Three independent experiments were performed to calculate the fold invasion relative to a blank control.
In vitro wound healing assays U87MG and U251MG cells were seeded in six-well plates and cultured until they reached confluence. A wound was then created by manually scraping the cell monolayer with a 200 lL pipette tip. Cell migration into the wound was observed at three preselected time points (0 and 24 hr) in six randomly selected microscopic fields for each condition and time point by microscopy.
Endothelial tube formation assay
U87 and U251 cells were cultured in each tumor supernatant and plated in a 96-well plate with Matrigel (BD Biosciences, NJ, USA) at a concentration 3 3 10 4 cells/well. Tumor supernatant was collected from each group subsequent to 24 hr culture in DMEM medium. Following 12 hr incubation with human umbilical vein cells (HUVECs), tubes were photographed by microscopy and evaluated.
Cell cycle and apoptosis assay
For cell cycle assay, cells were harvested by trypsinization after transfection for 48 hr, fixed with 70% ethanol at 2208C for at least 20 min. After extensive washing, cells were suspended again in PBS containing 50 lg/mL propidium iodide (PI; Sigma-Aldrich, MO, USA), 100 lg/mL RNase A (SigmaAldrich, MO, USA) and 1% Triton X-100 for 1 hr at room temperature, then analyzed by flow cytometry (FCM). For cell apoptosis assay, Annexin V-fluorescein isothiocyanate and PI double-staining (BD Biosciences, NJ, USA) were used to detect and quantify cellular apoptosis by FCM. All the tests were performed in triplicate.
Western blot assay
Total proteins were extracted from glioma cells with lysis buffer 48 hr after being transfected, and were quantified using protein assay kit (KeyGEN, Jiangsu, China). Sodium dodecyl sulfate polyacrylamide gel electrophoresis was performed on 20-40 lg of protein from each sample. The electrophoresed proteins were transferred to polyvinylidene difluoride membranes (Millipore, MA, USA) and incubated with diluted primary antibodies against NRP-1 (1:1,000; Abcam, Cambridge, UK), c-Myc, (phosphorylated) pPI3K, PI3K pERK, ERK, pAkt, Akt, pP65, P65 (1:1,000, Cell Signaling, MA, USA), b-actin(1:10,000, Abcam), followed by incubation with a horseradish peroxidase-conjugated secondary antibody (1:6,000; Santa Cruz, CA, USA). Beta-actin was used as a control (Santa Cruz).
Establishment of the PDX tumor model
All animal procedures were conducted in accordance with the care and use of laboratory animals' protocol approved by the institutional animal care committee of Southeast University. Female BALB/c nude mice were purchased from Shanghai Slac Laboratory Animal Technology Co., Ltd, Shanghai, China bred in aseptic conditions and kept at a constant humidity and temperature. For the PDX model of glioma, patient tumor specimens retrieved from operating room were sliced into small pieces (below 2-3 mm), implanted into the left sub-renal capsule of mice and propagated by serial transplantation. Depending on tumor tissue availability, tumor fragments were implanted in three mice. The mice used in these experiments were 6-8 weeks old. Mice were monitored daily for tumor development and sacrificed either on Day 28 after the injection of glioma cells or on Day 28. We recorded tumor volume and weight and then tumors were fixed in formalin and embedded in paraffin or snap frozen in liquid nitrogen.
Immunohistochemical analysis
Paraffin-embedded tumor tissue samples were cut into 5-mm sections. Slides were blocked with 10% goat serum and incubated with primary antibody directed against CD34 (1:100, Santa Cruz). Another day, the slides were incubated in goat anti-rabbit secondary antibody (Jackson, PA, USA). After incubating with diaminobenzidine (Beijing ZSGB Biotech, China), the colorimetric reaction was monitored under a light microscope. And sections were briefly counterstained with hematoxylin, then dehydrated, mounted and examined using an imager upright fluorescence microscope (Olympus, Japan).
Statistical analysis
Statistical analyses were performed using SPSS 19.0 and GraphPad Prism 5.0 software. Data were analyzed using the Student's t-test and ANOVA, shown as mean 6 standard deviation (x 6 s). The significance of the differences between different groups was tested by variance analysis (with p < 0.05 or p < 0.01 as significant).
Results
High-throughput sequencing detects miRNAs differentially expressed in glioma and normal brain tissues
We compared miRNAs expression in three pairs of human primary gliomas matched with normal brain tissues by illuminating Hiseq2500 high-throughput sequencing platform ( Table 1 ). The miRNA transcripts per million (TPM) was altered for at least twofold and the p-value < 0.05 between glioma and normal tissues was chosen for further analysis. Because of poor biological consistency in one pair tissues relative to another two, only the latter two pairs of tumortissues were used for further differential analysis. As a result, we identified 26 upregulated miRNAs and 17 downregulated miRNAs between glioma and normal brain tissues. As Figure  1a showed, hierarchical clustering of the high-throughput sequencing data generated a tree with a clear miRNA distinction between two major glioma and normal tissues. Next, we used miRWalk, TargetScan and miRanda databases to analyze potential targeted miRNAs and/or targeted NRP-1 genes. Only one miRNA (hsa-miR-124-3p) targeted NRP-1 among 43 differentially expressed miRNAs was selected through the aforementioned three databases for further investigation (Figs. 1a and 1b) .
hsa-miR-124-3p is downregulated in glioma tissues and cells as the opposite of NRP-1
We next examined miR-124-3p expression pattern in five human glioma tissues and normal brain tissues ( Table 1) . The results of quantitive RT-PCR showed that miR-124-3p was significantly downregulated in glioma tissues compared to normal brain tissues (Fig. 2a) . And miR-124-3p was also exhibited a low expression in all glioma cell lines (Fig. 2b) . Moreover, in line with our previous results, NRP-1 was overexpressed both in glioma tissues and in glioma cells (Figs. 2c  and 2d ). It showed that the expressed level of miR-124-3p was opposite to that of NRP-1 in gliomas, so we next examined the correlation between miR-124-3p and NRP-1 to verify whether NRP-1 was a targeted gene of miR-124-3p.
miR-124-3p interacts specifically with the 3 0 UTR region of
NRP-1 in glioma cells
Next, we wanted to obtain direct evidence that NRP-1 was a potential target gene of miR-124-3p, and to confirm the hypothesis that miR-124-3p could alter NRP-1 expression by posttranscriptional effects on the 3 0 UTR. Therefore, we constructed a luciferase reporter plasmid containing the entire 3 0 UTR region of NRP-1 and mutant plasmid of NRP-1 (named as pGL3M-NRP-1-3 0 UTR and mut) (Fig. 2e) . After co-transfected the U87 glioma cells with this vector along with either the miR-124-3p expression vector or its negative control, as shown in Figure 2f , the luciferase activity in the full-length Luc-NRP-1 3 0 UTR was significantly decreased by about 40% in luciferase units compared to the that in the miR-124-3p target site of mutant NRP-1 3 0 UTR or miR-124 mock control groups. The results unambiguously showed that miR-124-3p indeed targeted specifically the 3 0 UTR region of NRP-1, suggestingNRP-1 is a direct target of miR-124-3p in glioma cells. In addition, overexpression of miR-124 only reduced the NRP-1 WT expression level. Overexpression of miR-124-3p inhibits the proliferation, invasion and migration of glioma cells
Our previous studies have demonstrated that NRP-1 mAb can inhibit glioma cell proliferation and tumor growth via binding to its target in vitro and vivo. In our study, we showed that miR-124-3p can directly target NRP-1 3 0 UTR region, and the expression of miR-124-3p was negatively correlated with NRP-1 in gliomas. Therefore, we expected that the overexpression of miR-124 would have also a meaningful effect on glioma cells. First, we constructed a lentivirus encoding the mature sequence of miR-124-3p, and then infected with glioma cells to produce high level of miR-124-3p in glioma cells for further biological behavior assessment (Fig. 3a) . We used MTT assay to examine the effect of miR-124-3p on cell proliferation. As shown in Figure 3b , the rate of cell inhibition was significantly increased in the miR-124-3p group compared to the control groups at 24 and 48 hr after transfection (p <0.05), indicating that miR-124-3p inhibits the glioma cell proliferation. Next, transwell migration experiments revealed that overexpression of miR-124-3p in glioma cells suppressed the invasion of tumor cells compared to miR-NC (Negative Control) or control groups (Fig. 3c) . Likewise, the wound-healing assay also suggested that the miR-124-3p overexpressing group cells significantly restrained glioma cell migration compared to the control groups (Fig. 3d) . The results illustrated that all of the proliferation, invasion and migration of glioma cells were observably attenuated in miR-124-3p overexpressing U87 and U251 glioma cells. Furthermore, miR-124-3p overexpressing reversed NRP-1 expressing in both U87 and U251 glioma cells (Fig. 3e) . Together, it suggested that overexpression of miR-124-3p suppresses glioma cell proliferation, invasion and migration by inhibiting its target NRP-1 in vitro.
Restoration of miR-124-3p expression suppresses tumor angiogenesis
The growth of tumor normally accompanied with tumor angiogenesis so as to supply nutrition for tumor rapid proliferation or metastasis. We used tube formation assay to assess the role of miR-124-3p overexpression in glioma angiogenesis. The results revealed that overexpression of miR-124-3p in glioma cells also confined the tumor angiogenesis compared to miR-NC and control groups (Fig. 4a) . It indicated that miR-124-3p could be involved in glioma angiogenesis. 
miR-124-3p mediates cell cycle and apoptosis in glioma cells
The decrease in cell proliferation often accompanies the changes of cell cycle progression. To investigate the mechanism by which miR-124-3p regulates glioma cell proliferation, we performed cell cycle analysis on glioma cells overexpressing miR-124-3p. Flow cytometry analysis showed that overexpression of miR-124-3p increased the portion of glioma cells arrested in the G1/S phase but decreased the portion in the G2/M phases compared to the miR-NC group or control group (Fig. 4b) . The results suggested that miR-124-3p overexpression causes cell cycle arrested in the G1/S phase, although NRP-1 is able to stimulate glioma cell proliferation by promoting the G1/S phase transition. Next, we investigated whether overexpression of miR-124-3p induces apoptosis in glioma cells. Flow cytometry analysis of glioma cells overexpressed miR-124-3p for 48 hr showed that miR-124-3p overexpression significantly resulted in glioma cell apoptosis: the percentage of total apoptotic cells (early apoptotic cells 1 late apoptotic cells) increased by 37% or 41% in glioma cell lines compared to control or NC group (Fig. 4c) . These results suggested that miR-124-3p could mediate glioma cell cycle and survival/apoptosis.
Upregulation of miR-124-3p inhibits PI3K/Akt/NFjB but not ERK/c-Myc signaling pathways PI3K/Akt pathway is frequently activated in many types of human cancers. Phosphatidylinositol-3-kinase (PI3K) as a lipid kinase normally involves in regulation of cell proliferation, survival and invasion by triggering its major effectors Akt and transcription factors i.e. nuclear factor kappa B (NFjB). Several evidences suggest that the PI3K/Akt/NFjB signaling pathway may be associated with tumorigenesis. [21] [22] [23] However, whether downregulation of miR-124-3p promotes glioma progression via activation of PI3K/Akt/NFjB pathway needs to be investigated. As showed in Figure 4d , the western blotting of miR-124-3p overexpression on glioma cells determined that the expression of p-PI3K, p-Akt and p-p65 (NFjB) were significantly decreased compared to miR-NC or control group, but the total proteins of PI3K, Akt and p65 were constant. The results suggested that miR-124-3p can activate the PI3K/Akt/NFjB pathway in gliomas. In above context, we showed that when expression of miR-124-3p is restored, it can inhibit glioma cell proliferation and angiogenesis in vitro. Myc could be as an ERK-activated transcription factor and ERK/c-Myc pathway can promote tumor progression. 24, 25 However, overexpression of miR-124-3p increased the protein expression level of c-Myc (Fig. 4d) . Thus, miR-124-3p may affect tumor growth by inhibition of PI3K/Akt/ NFjB pathway but not ERK/c-Myc pathway in gliomas.
NRP-1 blocking antibody and miR-124-3p synergistically inhibit glioma growth
Malignant gliomas especially GBM involves multi-gene abnormality, so single target therapy usually fails to effectively treat tumors in current circumstances. Multi-target combined therapeutics represents the future trend for treatment of malignant gliomas. Our previous studies have screened out and produced NRP-1 mAb which effectively suppressed gliomas growth. In our study, we found that miR-124-3p is crucial for suppressing gliomas growth and development, and NRP-1 significantly synergize the effect of miR-124-3p in glioma cells. Therefore, to evaluate whether NRP-1 mAb could join with miR-124-3p to play synergistic effects in gliomas, we added NRP-1 mAb group and miR-124-3p 1 NRP-1 mAb group in the above experiments. And the results (Figs. 3 and 4) showed that significant synergistic inhibition effects were not only observed in inhibited glioma cell proliferation, invasion, migration, apoptosis and tumor angiogenesis, but this combination also weakened the PI3K/ We further sought to assess whether miR-124-3R suppresses the glioma growth in vivo. We used patient-derived tumor xenograft (PDX) model which is renewable tumor model engrafted in NOD/SCID mice generated from fresh human GBM for further analysis. PDX model is particularly suitable for pre-clinical testing because it recapitulates patients' tumor biology hallmarks with higher fidelity than tumor cell lines xenograft, and allows to effectively assess tumor evolution and therapy. Furthermore, PDX model has been applied to preclinical drug testing, biomarker identification, developing personalized treatment strategies for patients, etc.
We used three patients derived grade IV glioma to establish PDX models. The characteristics of patients and immunohistochemical images of H&E staining were shown in Figure 5a . At 24-day post-injection, the tumor was harvested from the mice in either control group or treatment group (mice received treatment of miR-124-3p virus and/or NRP-1 mAb). The results revealed that miR-124-3p inhibited tumor growth, and the mean volumes of xenograft tumors were significantly smaller compared to miR-NC or control groups, and NRP-1 mAb played synergistic antitumorigenesis effects (Fig. 5b) . H&E staining showed that the PDX tumors were originated from above patients (Fig. 5a ). Immunohistochemical staining for CD34 showed the expression of tumor angiogenesis was significantly decreased in miR-124-3p group compared to miR-control-groups (Fig. 5c ). And western blotting showed that the protein expression levels of NRP-1 and CD34 were significantly reduced (Fig. 5d) . Quantitative RT-PCR also revealed that the expression levels of NRP-1 and CD34 were markedly declined in the miR-124-3p virus group compared to miR-NC group or control group, while the miR-124-3p expression was elevated (Fig. 5e) . Furthermore, NRP-1 mAb played the synergistic effects with miR-124-3p overexpression virus. Thus, it appeared that miR-124-3p overexpression significantly inhibited the proliferation and growth of glioma cells in vivo via regulating the NRP-1 pathway.
Discussion
Tumor development is an orchestrated process accompanied by dysregulated expression of complex transcription and posttranscriptional genes. And miRNA targets diverse genes and plays important roles in post-transcriptional regulation of many cancer processes. 26, 27 Our previous studies [16] [17] [18] demonstrated that NRP-1 was overexpressed both in glioma cell lines and in glioma tissues, NRP-1 mAb can target the gliomas which then inhibits glioma cell proliferation and tumor growth, and NRP-1/GIPC1 pathway plays a vital role in glioma progression. However, the upstream signaling of NRP-1 which is putatively mediated by post-transcriptional regulation of miRNA was not clear. So in our study, we discovered miR- 124-3p was the upstream of NRP-1 by high-throughput sequencing and dual-luciferase reporter assay. Furthermore, the in vitro and in vivo experiment shown that NRP-1 is a direct functional target of miR-124-3p in gliomas, and overexpression of miR-124-3p suppresses glioma cell development and growth by inhibiting its target NRP-1.miR-124-3p has been documented as a tumor suppressor gene since low expression of miR-124-3p was observed in several types of human cancers, such as gliomas, gastric cancer, renal cell carcinoma, breast cancer, bladder cancer and ovarian cancer. [12] [13] [14] [28] [29] [30] [31] miR-124 has two mature forms named miR-124-3p (known as miR-124) and miR-124-5p (known as miR-124*). miR-124 is usually abundantly expressed in the mammalian brain cortex but significantly downregulated in human tumors which is correlated with poor prognosis in patients. Overexpression of miR-124-3p can cause cell cycle arrest, and inhibit cell migration and invasion in tumor cells. Liu et al. 28 investigated the miRNA expression profile as well as mRNA expression profile in normal human neural stem cells (hNSCs) and human glioma stem cells (hGSCs), and found that the expressions of miR-155-5p and miR-124-3p were significantly altered between GSCs and NSCs. Butz et al. 29 identified the miR-124-3p, miR-30a-5p and miR-200c-3p were the most significantly downregulated miRNAs in renal cell carcinoma (RCC) pathogenesis. Restoration of these miRNAs can reduce RCC cell proliferation, migration and invasion. They further identified CAV1 and FLOT1 as miR-124-3p targets, and miR-124-3p act as a key regulator of CAV1 and FLOT1 in RCC. Interestingly, Devaux et al. 32 assessed the prognostic value of circulating miRNAs in a large cohort of comatose patients with out-ofhospital cardiac arrest, and found that mean levels of miR-124-3p were higher in patients with a poor outcome compared to patients with a good outcome. Therefore, miR-124-3p may serve as a potential target tool for novel therapeutic strategies of several types of human diseases.
It is well acknowledged that high-throughput technology could be used to identify complex molecular processes of diseases. Over the last two decades, many mRNA and miRNA expression studies have been performed by using microarray or high-throughput sequencing. [33] [34] [35] And the differentially expressed miRNAs were identified by comparing to normal tissues. Then the target genes of differentially expressed miRNAs were predicted by bioinformatic algorithms (e.g., miRanda, miRDB, miRWalk, PICTAR and Targetscan). Generally, bioinformatics prediction of miRNA targets is more important than the research of miRNA function. Our previous studies [16] [17] [18] discovered that NRP-1 was overexpressed in both glioma tissues and cells. In our study, we firstly explored the upstream components of NRP-1 that may play a role in post-transcriptionally regulating NRP-1. We identified 26 upregulated miRNAs and 17 downregulated miRNAs between glioma and normal brain tissues by high-throughput sequencing, and selected one intersecting miRNA targeted NRP-1: hsa-miR-124-3p by dual targeted bioinformatics analysis of miRWalk, TargetScan and miRanda databases. The miR-124-3p could interact specifically with the 3 0 UTR region of NRP-1 in glioma cells, and it was further validated by dual luciferase reporter experiment. miR-124-3p was downregulated in glioma tissues and cells, and reversed NRP-1 expressing in glioma cell lines. To our delight, overexpressed miR-124-3p evidently inhibited glioma cell proliferation, migration, tumor-angiogenesis and resulted in glioma cell apoptosis and cell cycle arrest via activated PI3K/Akt/NFjB pathways by targeted NRP-1 in vitro and in vivo PDX model. Here, we added NRP-1 mAb which were produced by ourselves as positive control and synergized with miR-124-3p overexpression virus, and we found that they could exert much more synergistic inhibited effects on glioma development and growth. Thus, we determined that miR-124-3p should act in the upstream of NRP-1 and regulate glioma cell development and growth by direct suppressing NRP-1 expression in gliomas.
In conclusion, glioblastoma as a multi-gene abnormality disease has been verified with diverse transcription or posttranscriptional gene (or suppressor genes/oncogene) involvement in its development. Our previous studies have assessed the roles of NRP-1 and its downstream pathway in gliomas. Here we further revealed miR-124-3p was the upstream regulator of NRP-1, and could specially bound to the 3 0 UTR region of the NRP-1. Our study reported that miR-124-3p plays a vital role in mediating glioma proliferation or growth by specifically targeting NRP-1. Thus, we have explored the valuable study that miR-124-3p/NRP-1/GIPC1 has an important role in gliomas, by mediating the downstream PI3K/Akt/NFjB and KRAS/ERK signaling pathway to promote tumorigenicity and tumor angiogenesis (Fig. 5f) . And, miR-124-3p/NRP-1/GIPC1 as a newly pathway could be considered as the potential meaningful target of multi-gene therapy in gliomas in future.
